NIAID chemokine discovery may chart new course for HIV
This article was originally published in Scrip
Like most stories of discovery, the unearthing by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) of a link between the protein CXCL4 and HIV suppression may still be far from a happy ending, in this case, potential translation into an effective treatment, preventive therapy or vaccine, explained Dr Paolo Lusso, chief of the viral pathogenesis section in the agency's Laboratory of Immunoregulation Scientists directed by NIAID chief Dr Anthony Fauci.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.